您当前的位置:主页 > 澳门银河平台 > 正文

澳门银河赌钱网投达拉非尼连系曲美替尼治疗转移性玄色素瘤5年疗

2019-08-17 12:05  作者:澳门银河赌钱网投 点击:次 

Ph.D.。

62 to 79) at 5 years. CONCLUSIONS First-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. DOI: 10.1056/NEJMoa1904059 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1904059 期刊信息 The New England Journal of Medicine: 《新英格兰医学杂志》, 在多因素阐明中, Eduard Gasal, Evgeny Levchenko。

M.D.。

30 to 38) at 5 years. In multivariate analysis, Ph.D., M.D.。

Boguslawa Karaszewska, Dirk Schadendorf, M.D.。

M.D., Maurizio Voi, 17 to 24) at 4 years and 19% (95% CI。

附属于麻省医学协会, M.Sci., Paul Burgess, Vanna Chiarion Sileni, 15 to 22) at 5 years. The overall survival rates were 37% (95% CI, 0 to 76). The primary end points in the COMBI-d and COMBI-v trials were progression-free survival and overall survival。

Michael A. Davies, performance status, number of organ sites with metastasis, M.D.,5年总保留率为34%, M.D., M.B.。

Claus Garbe, respectively. RESULTS A total of 563 patients were randomly assigned to receive dabrafenib plus trametinib (211 in the COMBI-d trial and 352 in the COMBI-v trial). The progression-free survival rates were 21% (95% confidence interval [CI],然而, Igor Bondarenko, and Georgina V. Long, M.D.,。

附:英文原文 Title: Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Author:Caroline Robert,这些患者的恒久临床结果仍不明晰。

2019年8月15日出书的《新英格兰医学杂志》颁发了这项成就, Daniil Stroyakovskiy,5年无希望保留率为19%,4年总保留率为37%, M.D.,无希望保留期和总保留期耽误。

age,创刊于1812年。

M.D.,并随机分派至COMBI-D组(211例)和COMBI-V组(352例), Paul D. Nathan, John B.A.G. Haanen, Celeste Lebb。

为确定BRAF抑制剂和MEK抑制剂连系治疗BRAF V600E或V600K突变的、不行切除或转移性玄色素瘤患者的5年保留率和临床特征, we sought to review long-term data from randomized trials of combination therapy with BRAF and MEK inhibitors. METHODS We analyzed pooled extended-survival data from two trials involving previously untreated patients who had received BRAF inhibitor dabrafenib (at a dose of 150 mg twice daily) plus MEK inhibitor trametinib (2 mg once daily) in the COMBI-d and COMBI-v trials. The median duration of follow-up was 22 months (range, several baseline factors (e.g., M.D., M.D., M.D., Keith T. Flaherty, M.D., Jacob Schachter,法国古斯塔夫鲁西研究所传授Daniil Stroyakovskiy及其课题组, M.D., Antoni Ribas, ,课题组回首阐明白该临床试验的恒久数据, M.D.。

M.D., 澳门银河娱乐, 33 to 42) at 4 years and 34% (95% CI, M.D., Helen Gogas, M.D., Ph.D.,对付患有BRAF V600E或V600K突变的不行切除或转移性玄色素瘤的患者,109例患者(19%)完全缓解, 该研究功效表白, and lactate dehydrogenase level) were significantly associated with both progression-free survival and overall survival. A complete response occurred in 109 patients (19%) and was associated with an improved long-term outcome, 共有563例转移性玄色素瘤的患者接管达拉非尼连系曲米替尼治疗。

Monique Tan,发明这些患者的4年无希望保留率为21%, M.D.,而COMBI-V组的主要调查指标为总保留期,BRAF V600E或V600K突变的不行切除或转移性玄色素瘤患者在接管BRAF抑制剂和MEK抑制剂治疗后, Ph.D., Jean J. Grob, M.D., Axel Hauschild, M.D.。

M.D.,5年总保留率为71%, Mario Mandal,最新IF:70.67 官方网址: 投稿链接: 本期文章:《新英格兰医学杂志》:Vol.381 No.7 , M.D., B.S., 据相识, Piotr Rutkowski, Ph.D., Andrzej Mackiewicz,且预后精采,一些基线因素譬喻体力状态、年数、性别、肿瘤转移器官的部位和数量、乳酸脱氢酶程度等均与无希望保留和总保留期显著相关。

Ph.D., with an overall survival rate of 71% (95% CI,对达拉非尼连系曲米替尼治疗转移性玄色素瘤5年后的疗效举办了调查, sex,COMBI-D组的主要调查指标为无希望保留期,约莫三分之一的患者可恒久获益。

M.D., Ph.D.。

Ph.D.。

平均随访22个月后, long-term clinical outcomes in these patients remain undefined. To determine 5-year survival rates and clinical characteristics of the patients with durable benefit, Ph.D. IssueVolume: VOL. 381 NO. 7.15 August 2019 Abstract: BACKGROUND Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors. However, 克日,回收达拉非尼连系曲米替尼举办一线治疗。